BioWorld Asia

Aug. 10, 2005

Santhera Licenses European Idebenone Rights To Takeda

Santhera Pharmaceuticals AG licensed to Takeda the European rights to its Friedreich's Ataxia (FRDA) treatment, idebenone, in a deal which earned it an up-front payment of EUR5 million (US$6.2 million). (BioWorld International) Read More

£12M For Intercytex Will Fund Wound Product Phase III Trial

Maintaining Chromosome Ends Influences Stem Cell Behavior

Stallergènes Has Common Allergy Treatment Focus

Oxford Immunotec Gets £7M To Broaden Reach Of TB Test

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 13, 2026.

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...